Premium
Fecal biomarkers in inflammatory bowel disease
Author(s) -
Lopez Robert N,
Leach Steven T,
Lemberg Daniel A,
Duvoisin Gilles,
Gearry Richard B,
Day Andrew S
Publication year - 2017
Publication title -
journal of gastroenterology and hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.214
H-Index - 130
eISSN - 1440-1746
pISSN - 0815-9319
DOI - 10.1111/jgh.13611
Subject(s) - calprotectin , medicine , inflammatory bowel disease , lactoferrin , context (archaeology) , ulcerative colitis , disease , inflammatory bowel diseases , gastroenterology , feces , endoscopy , paleontology , biology , genetics
Over the last two decades, knowledge on fecal biomarkers has substantially increased. Nowadays, these non‐invasive markers of inflammation have significant clinical utility in the management of inflammatory bowel disease. Their use informs the decision to perform endoscopy before diagnosis is made right through to influencing therapeutic choices and the need for interval endoscopic assessment. In this review, the roles of two S100 proteins, calprotectin, and S100A12 are described along with that of lactoferrin, in the context of inflammatory bowel disease.